Cryopreservation standards for stem cell storage

Introduction

Cryopreservation refers to the scientific process of preserving biological materials, including stem cells, at extremely low temperatures to maintain their viability and biological characteristics for future use. It is an essential technique in regenerative medicine, transplantation, biomedical research, fertility treatment, and advanced cellular therapies.

Stem cells have the ability to differentiate into specialised cell types and are therefore valuable for treating or investigating various medical conditions. However, their biological properties may deteriorate if they are not collected, processed, stored, and transported under appropriate conditions.

Cryopreservation standards for stem cell storage refer to the scientific, technical, ethical, and legal requirements governing the preservation of stem cells. These standards regulate donor consent, cell collection, processing, quality testing, temperature control, storage facilities, documentation, transportation, and eventual clinical application.

The primary objective is to ensure that preserved stem cells remain safe, viable, traceable, and suitable for their intended medical or research purposes. Effective regulation also protects donors, patients, research participants, and healthcare institutions from improper storage practices and unverified therapeutic claims.

International legal and regulatory framework

International regulation of stem cell cryopreservation involves several organisations and regulatory instruments.

The World Health Organization (WHO) has developed principles concerning human cell, tissue, and organ transplantation. Its Guiding Principles emphasise voluntary donation, informed consent, quality assurance, traceability, and ethical handling of human biological materials.

The International Society for Cell and Gene Therapy (ISCT) and professional organisations such as the Foundation for the Accreditation of Cellular Therapy (FACT) have also developed technical standards relevant to cellular therapy facilities.

FACT–JACIE standards establish quality and safety requirements for cellular therapy programmes, including collection, processing, storage, transportation, and administration of cellular products.

In the European Union, Regulation (EC) No. 1394/2007 governs advanced therapy medicinal products (ATMPs), including certain stem cell-based medicinal products. Regulation (EU) No. 536/2014 also establishes requirements concerning clinical trials involving medicinal products.

Additionally, the EU Tissues and Cells regulatory framework has historically governed human tissues and cells intended for human application. Regulation (EU) 2024/1938 establishes a new framework for substances of human origin (SoHO), including human cells and tissues, with phased application beginning in 2027.

These regulatory instruments demonstrate the importance of maintaining consistent safety and quality standards throughout the biological storage process.

Cryopreservation standards and technical requirements

Stem cell cryopreservation requires scientifically validated procedures to minimise cellular damage during freezing, storage, and thawing.

The principal technical requirements include the following.

1. Collection and processing standards

Stem cells may be collected from bone marrow, peripheral blood, umbilical cord blood, or other legally permitted biological sources.

Collection facilities must establish procedures for donor identification, eligibility assessment, informed consent, infection screening, and sample labelling.

Processing facilities must maintain documented procedures for cell separation, concentration, testing, and preparation before cryopreservation.

2. Temperature control

Long-term stem cell preservation commonly uses liquid nitrogen storage systems or validated vapour-phase nitrogen systems operating at cryogenic temperatures.

Storage conditions must be scientifically validated for the particular cellular product. Facilities should continuously monitor temperature and establish alarm systems for deviations.

Temperature records should be maintained to demonstrate that preserved materials have remained within approved storage conditions.

3. Cryoprotective agents

Cryoprotective agents are used to reduce cellular damage during freezing.

Dimethyl sulfoxide (DMSO) is commonly used in the cryopreservation of certain stem cell products. However, its concentration, exposure, removal, and potential toxicity must be evaluated according to the specific cellular product and validated protocol.

4. Quality control and viability testing

Before storage and, where appropriate, before clinical release, stem cell products must undergo relevant quality assessments.

These may include:

Cell viability testing.

Cell identity and purity assessment.

Sterility testing.

Endotoxin testing.

Mycoplasma testing where appropriate.

Cell count and potency assessment.

Evaluation of relevant biological characteristics.

The testing requirements depend on the type of stem cells and their intended clinical or research application.

5. Storage facility requirements

Cryopreservation facilities must maintain controlled environments, validated storage equipment, backup systems, emergency response arrangements, and trained personnel.

They should also establish procedures for equipment failure, nitrogen supply interruptions, power outages, and accidental sample exposure.

Regulation under Indian law

India regulates stem cell research and related activities through a combination of biomedical research legislation, clinical research requirements, laboratory standards, and institutional ethical guidelines.

The principal regulatory framework includes the following:

1. National Guidelines for Stem Cell Research, 2017

The Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT) issued the National Guidelines for Stem Cell Research, 2017.

These guidelines establish requirements concerning stem cell procurement, research, banking, processing, clinical applications, and institutional oversight.

They distinguish between permissible basic research, regulated clinical research, and prohibited activities.

The guidelines also address the responsibilities of Institutional Committees for Stem Cell Research (IC-SCR) and the National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT).

2. Drugs and Cosmetics Act, 1940

Stem cell-based products intended for therapeutic use may fall within the regulatory framework governing drugs and biological products, depending on their characteristics and intended application.

The Drugs and Cosmetics Act, 1940, together with the applicable New Drugs and Clinical Trials Rules, 2019, establishes requirements concerning relevant approvals, clinical investigations, manufacturing standards, and quality controls.

3. Biomedical Waste Management Rules, 2016

Facilities handling biological materials must comply with applicable biomedical waste management requirements.

These Rules regulate the segregation, handling, treatment, and disposal of biomedical waste generated during collection, processing, and laboratory operations.

4. Digital Personal Data Protection Act, 2023

Where stem cell banking involves digital personal data relating to identifiable donors or patients, applicable data protection requirements must be considered.

Relevant information may include donor identification records, medical histories, genetic information, and clinical records.

Donor consent and ownership of stored stem cells

Informed consent is a fundamental requirement in stem cell banking.

Donors should receive clear information about the purpose of collection, storage duration, possible future applications, access rights, confidentiality, and the circumstances in which biological material may be used or transferred.

Private cord blood banking also raises important questions concerning ownership, control, and future access to stored biological material.

The storage agreement should clarify:

The identity of the donor and authorised recipient.

The institution responsible for storage.

The permitted purposes of preservation.

Storage fees and contractual responsibilities.

Conditions for release or transfer of stored material.

Procedures for withdrawal or disposal.

Confidentiality and genetic information protection.

Responsibilities in the event of institutional closure.

A commercial storage agreement cannot guarantee that preserved stem cells will necessarily be suitable for future treatment. Their clinical usefulness depends on biological characteristics, quality, compatibility, and medical suitability.

Traceability and transportation requirements

Stem cell storage facilities must maintain reliable identification and traceability systems.

Each biological sample should have a unique identification reference linking it to the relevant donor, collection event, processing records, testing results, and storage location.

Traceability becomes especially important when samples are transferred between institutions or transported internationally.

International transportation may also require compliance with applicable customs, biological material transportation, dangerous goods, and import-export regulations.

Institutions should maintain records of:

Donor identification and consent.

Collection date and source.

Processing and quality testing.

Storage location and temperature history.

Transfer and transportation records.

Release and clinical administration details.

Important judicial decisions and case laws

1. Moore v. Regents of the University of California, 51 Cal. 3d 120 (1990)

The Supreme Court of California examined a dispute involving the use of a patient's biological materials for scientific research without adequate disclosure of the researcher's financial interests.

The Court rejected the patient's conversion claim concerning the excised cells but recognised potential legal liability based on failure to disclose relevant conflicts of interest.

The judgment is important for stem cell banking because it highlights the importance of informed consent, transparency, and disclosure of commercial interests when human biological materials are collected and used for research.

2. Greenberg v. Miami Children's Hospital Research Institute, Inc., 264 F. Supp. 2d 1064 (S.D. Fla. 2003)

The United States District Court considered a dispute involving genetic research materials and intellectual property arising from contributions made by families affected by Canavan disease.

The case addressed issues involving informed consent, research contributions, ownership claims, and commercialisation of genetic discoveries.

It is relevant to stem cell banking because stored biological materials may generate valuable research findings and commercial products. Institutions must therefore establish transparent consent and material-use arrangements.

3. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

The United States Supreme Court examined the patentability of isolated human genes and synthetically created complementary DNA.

The Court held that naturally occurring DNA does not become patentable merely because it has been isolated, while synthetically created cDNA may qualify for patent protection, subject to applicable requirements.

The judgment is relevant to stem cell storage because preserved biological samples may contain genetic information that becomes the subject of subsequent scientific research and intellectual property disputes.

4. Washington University v. Catalona, 490 F.3d 667 (8th Cir. 2007)

The United States Court of Appeals considered ownership and control of biological research specimens collected from human participants and maintained by a university.

The Court concluded that the university, rather than the individual researcher, controlled the relevant research specimens under the circumstances of the case.

The judgment is particularly relevant to stem cell banking because it illustrates the importance of institutional ownership policies, donor consent documentation, and contractual arrangements governing stored biological materials.

5. Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1

The Supreme Court of India recognised privacy as a fundamental right under Article 21 of the Constitution.

The judgment established important principles concerning informational privacy, individual autonomy, and protection against arbitrary disclosure of personal information.

It is relevant to stem cell storage because biological samples may contain identifiable genetic and medical information. Storage institutions must therefore protect donor confidentiality and ensure that personal information is processed according to applicable legal requirements.

Responsibilities of stem cell storage institutions

Stem cell banks, hospitals, research laboratories, and biotechnology companies must maintain comprehensive quality and compliance systems.

Their principal responsibilities include:

Obtaining valid donor consent before collection.

Following applicable stem cell research guidelines.

Maintaining validated cryopreservation procedures.

Ensuring continuous temperature monitoring.

Conducting appropriate quality and viability assessments.

Maintaining secure and traceable storage systems.

Protecting donor identity and genetic information.

Employing trained laboratory personnel.

Establishing emergency storage and equipment-failure procedures.

Maintaining records of sample transfers and release.

Preventing unauthorised commercial or clinical use.

Institutions must also ensure that experimental stem cell products are not presented as approved treatments without the required regulatory authorisation.

Challenges in cryopreservation regulation

Cryopreservation regulation faces several scientific, legal, and institutional challenges.

One major difficulty is maintaining long-term biological quality. Even when samples remain at cryogenic temperatures, their suitability for future clinical applications must be established through appropriate quality assessment.

Another challenge concerns the absence of identical regulatory standards across countries. Different jurisdictions may impose different requirements for donor consent, sample ownership, laboratory accreditation, clinical use, and international transportation.

Additional challenges include:

Long-term storage responsibility and institutional continuity.

Equipment failure and temperature monitoring.

Unclear contractual ownership of stored samples.

Protection of genetic and medical information.

Commercialisation of stored biological materials.

International transfer and customs restrictions.

Inadequate quality control in unregulated storage facilities.

Unsubstantiated claims concerning future therapeutic benefits.

Regulatory authorities must therefore promote scientific standardisation, independent inspections, transparent contracts, and effective enforcement mechanisms.

Conclusion

Cryopreservation standards for stem cell storage are essential for maintaining the safety, quality, viability, and long-term traceability of preserved biological materials. International standards developed by organisations such as WHO and FACT, together with India's National Guidelines for Stem Cell Research, 2017, provide important foundations for responsible stem cell banking. The Drugs and Cosmetics Act, 1940, applicable clinical trial regulations, and relevant privacy requirements further strengthen the regulatory framework. Judicial decisions such as Moore v. Regents, Greenberg v. Miami Children's Hospital, Washington University v. Catalona, and Puttaswamy v. Union of India provide important principles concerning informed consent, biological material control, intellectual property, and privacy. Ultimately, effective cryopreservation governance requires scientifically validated storage procedures, transparent donor agreements, institutional accountability, and continuous quality monitoring to ensure that preserved stem cells remain suitable for their intended research or clinical purposes.